Navigation Links
Discovery Sheds Light on Huntington's Disease
Date:6/4/2009

Researchers identify protein that could lead to treatment or prevention

THURSDAY, June 4 (HealthDay News) -- Scientists have pinpointed a protein that plays a key role in cell death in Huntingdon's disease, a degenerative disorder that leads to uncontrolled movements and loss of intellectual functioning.

The discovery raises hope that drugs could be developed to slow or halt the disease, according to a study in the June 5 issue of Science.

In Huntington's disease, cells in the corpus striatum, the area of the brain that controls movement, gradually die off.

Previous research has shown that people with Huntington's have a genetic defect that produces a mutant version of the protein "huntingtin," which accumulates in cells throughout the body.

But for reasons scientists didn't understand, the protein only kills cells in the corpus striatum. The protein causes little damage to tissues elsewhere.

In the new study, researchers discovered that a tiny protein called "rhes" -- found only in the corpus striatum -- interacts with the mutant huntingtin proteins, causing cell death.

The findings explain the pattern of brain damage in Huntington's disease and suggest strategies for developing new drug therapies, researchers at Johns Hopkins University said.

"It's always been a mystery why, if the protein made by the HD (Huntington's disease) gene is seen in all cells of the body, only the brain, and only a particular part of the brain, the corpus striatum, deteriorates," said Dr. Solomon H. Snyder, a professor of neuroscience at Johns Hopkins. "By finding the basic culprit, the potential is there to develop drugs that target it and either prevent symptoms or slow them down."

Huntington's is a familial disease, passed from parent to child through a gene mutation. A child of someone with Huntington's has a 50-50 chance of inheriting the gene, according to the National In
'/>"/>

Copyright©2009 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3

Related medicine news :

1. Discovery of sugar sensor in intestine could benefit diabetes
2. Discovery suggests location of genes for breast density, a strong risk factor for breast cancer
3. Stem cell research produces a key discovery for Fragile X Syndrome
4. Welch Foundation gives $1.6 million for drug discovery research
5. New discovery leaves blood-doping athletes scratching their heads
6. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
7. New discovery leaves blood-doping athletes scratching their heads
8. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
9. Discovery supports theory of Alzheimers disease as form of diabetes
10. Discovery Health CME Explores the Benefits and Risks of Aspirin in Aspirin Therapy: Maximizing the Benefits
11. New discovery may improve treatment of one of the worlds leading causes of blindness
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Discovery Sheds Light on Huntington's Disease 
Discovery Sheds Light on Huntington's Disease
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Lack of happiness hormone serotonin in the brain causes impaired maternal behavior in mice 8972 1Energy saving method checks refrigerant level in air conditioners 8970 1Energy saving method checks refrigerant level in air conditioners 8970 2How to text message and avoid pain 8968 1How to text message and avoid pain 8968 2